CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue

[1]  R. Mesa,et al.  Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. , 2000, Blood reviews.

[2]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[3]  D. Nagorney,et al.  Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. , 2000, Blood.

[4]  M. Le Bousse-Kerdilès,et al.  Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis , 1999, Annals of Hematology.

[5]  G. Barosi.  Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Porcu,et al.  Splenectomy in agnogenic myeloid metaplasia. , 1999, Blood.

[7]  S Quaglini,et al.  Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. , 1998, Blood.

[8]  B. Swolin,et al.  Increase of CD34 positive cells in polycythaemia vera , 1997, European journal of haematology.

[9]  Y. Najean,et al.  Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. , 1994, Nouvelle revue francaise d'hematologie.

[10]  N. Heerema,et al.  CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia. , 1994, American journal of clinical pathology.

[11]  S. Quaglini,et al.  Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. , 1993, Leukemia.

[12]  J. Thiele,et al.  Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: immunohistochemical and morphometric evaluation of proliferative activity of erythro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining) , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.

[13]  J. Thiele,et al.  Splenic Megakaryocytopoiesis in Primary (Idiopathic) Osteomyelofibrosis , 1992 .

[14]  J. Thiele,et al.  Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features. , 1992, Acta haematologica.

[15]  J. Liesveld,et al.  Adhesive interactions of normal and leukemic human CD34+ myeloid progenitors: role of marrow stromal, fibroblast, and cytomatrix components. , 1991, Experimental hematology.

[16]  J. Benbassat,et al.  The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia , 1990, American journal of hematology.

[17]  V. Praloran,et al.  Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. , 1989, Blood.

[18]  F. Gudat,et al.  Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders , 1989, European journal of haematology.

[19]  J. Abgrall,et al.  Characteristics of circulating megakaryocyte progenitors (CFU‐MK) in patients with primary myelofibrosis , 1988, European journal of haematology.

[20]  L. Vannucchi,et al.  Megakaryocyte progenitors in the bone marrow and peripheral blood of patients with myeloproliferative diseases , 1987, American journal of hematology.

[21]  Wolf Bc,et al.  Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. , 1987 .

[22]  R. Neiman,et al.  Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. , 1987, Hematologic pathology.

[23]  L. Douay,et al.  Blood and spleen haematopoiesis in patients with myelofibrosis. , 1987, Leukemia research.

[24]  E. Juvonen,et al.  Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis. , 2009, Scandinavian journal of haematology.

[25]  R. Neiman,et al.  Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. , 1985, Blood.

[26]  S. Lewis,et al.  Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders , 1984, British journal of haematology.

[27]  R. Neiman,et al.  Evidence to suggest that the human fetal spleen is not a hematopoietic organ. , 1983, American journal of clinical pathology.

[28]  D. Douer,et al.  Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders , 1983, British journal of haematology.

[29]  M. S. Tobin,et al.  Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis , 1983, British journal of haematology.

[30]  P. Vuopio,et al.  Circulating haematopoietic progenitors in myelofibrosis. , 2009, Scandinavian journal of haematology.

[31]  J. Goldberg,et al.  The Spleen as a Site of Colony-Forming Cell Production in Myelofibrosis 1 , 1980, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[32]  H. Koeffler,et al.  Splenic Irradiation in Myelofibrosis: Effect on Circulating Myeloid Progenitor Cells , 1979, British journal of haematology.

[33]  E. Cronkite,et al.  Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia , 1978, American journal of hematology.

[34]  P. Chervenick.  Increase in circulating stem cells in patients with myelofibrosis. , 1973, Blood.